Inventor
VOLPI SIMONA
US15 patents
⚠️ This page may combine multiple inventors who share the name “VOLPI SIMONA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
LAVEDAN CHRISTIAN
8 patentsUS9328387B2May 3, 2016
Antipsychotic treatment based on SNP genotype
LAVEDAN CHRISTIAN16 citations92
US9080214B2Jul 14, 2015
Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
LAVEDAN CHRISTIAN8 citations83
US9074255B2Jul 7, 2015
Method of predicting a predisposition to QT prolongation
LAVEDAN CHRISTIAN6 citations82
US9072742B2Jul 7, 2015
Method of predicting a predisposition to QT prolongation
LAVEDAN CHRISTIAN6 citations82
US9074256B2Jul 7, 2015
Method of predicting a predisposition to QT prolongation
LAVEDAN CHRISTIAN6 citations82
US8652776B2Feb 18, 2014
Prediction of QT prolongation based on SNP genotype
LAVEDAN CHRISTIAN12 citations80
US9074254B2Jul 7, 2015
Method of predicting a predisposition to QT prolongation
LAVEDAN CHRISTIAN6 citations69
US9057104B2Jun 16, 2015
Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
LAVEDAN CHRISTIAN1 citations61
VANDA PHARMACEUTICALS INC
7 patentsUS9458507B1Oct 4, 2016
Antipsychotic treatment based on SNP genotype
VANDA PHARMACEUTICALS INC7 citations83
US10563261B2Feb 18, 2020
Method of predicting a predisposition to QT prolongation
VANDA PHARMACEUTICALS INC2 citations72
US10570452B2Feb 25, 2020
Method of predicting a predisposition to QT prolongation
VANDA PHARMACEUTICALS INC1 citations62
US10563260B2Feb 18, 2020
Method of predicting a predisposition to QT prolongation
VANDA PHARMACEUTICALS INC1 citations62
US9408839B2Aug 9, 2016
Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
VANDA PHARMACEUTICALS INC1 citations62
US9243295B2Jan 26, 2016
Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
VANDA PHARMACEUTICALS INC1 citations62
US10570453B2Feb 25, 2020
Method of predicting a predisposition to QT prolongation
VANDA PHARMACEUTICALS INC1 citations59